BVS - Bioventus Corp Price Target Chart

Regular deliveries to surgical centers create a reliable cash flow, while an established product portfolio serves as the revenue foundation for Bioventus Inc. (BVS). Simultaneously, the company is implementing advanced biomaterials to accelerate tissue recovery and combat chronic pain. The price action, where the consensus forecast is 16.55, is presented in the chart below. Stable demand for orthopedic solutions and the share of consumables guarantee high margins and a strong free cash flow.

Bioventus (BVS): Price Target Chart from 07/04/2022 to 11/11/2026

Analytical breakdowns for Bioventus Corp (BVS)

- current price and projected stock value:

Price Chart bioventus.com|BVS - Consensus Target

- market capitalization statistics:

Market Value Bioventus Corp|BVS - Total Company Value

- issuer book value statistics:

Net Assets per Share Bioventus|BVS - Company Book Value|Market Capitalization to Book Value bioventus.com|BVS - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

BVS - Company Net Income|Expected Profit Bioventus Inc.|BVS - P/E Multiple|Market Cap to Projected Earnings Bioventus Inc|BVS - Price/Earnings to Growth Multiple|Company Value to Operating Income Before Depreciation Ratio Bioventus Corp|BVS - Operating profit EBITDA|Net earnings per one share for the last twelve months Bioventus|BVS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months bioventus.com|BVS - Net earnings per share growth this year|Expected earnings per share trend next year Bioventus Inc.

General company analysis:BVS (bioventus.com)

This indicator determines the estimated target value where current market quotes and minimum profitability reach equilibrium. Investors utilize the consensus share price forecast to analyze liquidity and identify hidden large orders. This tool enables an assessment of real growth potential without market vacuums. For Bioventus Inc. (BVS), such levels confirm the stability of its capitalization. Steady revenue from the sale of bone implants and fracture healing systems fundamentally supports these values.

Competing companies